Paxlovid

See: Post-Exposure Prophylaxis, Antiviral Drug, Therapeutic Goods Administration, Oral Administration, Pfizer, European Medicines Agency, COVID-19, Antiviral Medication, Nirmatrelvir.

References

(Wikipedia, 2022) ⇒ https://en.wikipedia.org/wiki/Nirmatrelvir/ritonavir Retrieved:2022-5-23.
- Nirmatrelvir/ritonavir, sold under the brand name Paxlovid, is a co-packaged oral medication used as a treatment for COVID-19.^[1]^[2] It contains the antiviral medications nirmatrelvir and ritonavir.
  In December 2021, nirmatrelvir/ritonavir was granted emergency use authorization by the United States Food and Drug Administration (FDA) for the treatment of COVID-19.^[3] It is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in those requiring hospitalization due to severe or critical COVID-19. It was fully approved in the United Kingdom later that month, and in the European Union and Canada in January 2022.

↑ Cite error: Invalid <ref> tag; no text was provided for refs named Paxlovid SmPC
↑ Cite error: Invalid <ref> tag; no text was provided for refs named Paxlovid FDA label
↑ Cite error: Invalid <ref> tag; no text was provided for refs named fda-factsheet

(Wen et al., 2022) ⇒ Wen Wen, Chen Chen, Jiake Tang, Chunyi Wang, Mengyun Zhou, Yongran Cheng, Xiang Zhou et al. (2022). “Efficacy and Safety of Three New Oral Antiviral Treatment (molnupiravir, Fluvoxamine and Paxlovid) for COVID-19： a Meta-analysis.” In: Annals of Medicine, 54(1).
- QUOTE: ... This study showed that three novel oral antivirals (molnupiravir, fluvoxamine and Paxlovid) are effective in reducing the mortality and hospitalization rates in patients with COVID-19. In addition, the three oral drugs did not increase the occurrence of adverse events, thus exhibiting good overall safety. ...

(Mahase, 2021) ⇒ Elisabeth Mahase. (2021). “Covid-19: Pfizer’s Paxlovid is 89% Effective in Patients at Risk of Serious Illness, Company Reports.” BMJ. 2021;375:n2713
- QUOTE: ... Pfizer’s oral antiviral drug paxlovid significantly reduces hospital admissions and deaths among people with covid-19 who are at high risk of severe illness, when compared with placebo, the company has reported.
  The interim analysis of the phase II-III data, outlined in a press release, included 1219 adults who were enrolled by 29 September 2021. It found that, among participants who received treatments within three days of covid-19 symptoms starting, the risk of covid related hospital admission or death from any cause was 89% lower in the paxlovid group than the placebo group. ...